In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.
Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.
“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.
“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.
Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly.
While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.
Posted by AGORACOM-JC
at 6:17 PM on Monday, July 5th, 2021
With $US 3.2M in 2020 revenue, representing a 58% increase over the previous year, you would think Empower Clinics CEO Steve McAuley would use his first interview after the filing to celebrate.
He isn’t.
Rather, with Fiscal 2020 having come to end more than 6 months ago, the 2020 results are a distant rear view mirror shot of a Company that is in full-blown growth mode and can be best summarized as follows:
“Multiple opportunities have been percolating and I’m going to turn up the heat”
To this end McAuley sees a “substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”.
We could try to list all the powerful things he had to say in this interview – but best we let you watch/hear it straight from Steve in this amazing interview.
Posted by AGORACOM-JC
at 12:23 PM on Monday, July 5th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
The smile on CEO Steve Saviuk says it all. The company recently released Q2 results and highlights:
Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter
Q3-21 revenues expected to increase by more than 50% over Q2-21
Redesca (blood thinner) launched in late Q2-21
Commercial shipments of the company’s asthma drugs commenced following national respiratory sales force deployment
Closed upsized $6.645 million debenture placement
Closed $11.5 million bought deal
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer discuss how to integrate a psychedelic experience into everyday life.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer are joined by Derick Moody, PA-C, to discuss the role that the inner healing intelligence plays in psychedelic medicine.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer discuss the historically messy relationship between spirituality and modern psychiatry and the role that psychedelics are playing in a spiritual renaissance.
The Podcast is hosted by Novamind’s Dr. Stephen Thayer, Clinical Director, Education & Training and Dr. Reid Robison, Chief Medical Officer. Weekly Podcast episodes feature conversations between Dr. Thayer and Dr. Robison about issues that are of special interest to the psychedelic medicine and research community.
“Psychedelics are the next frontier of psychiatric medicine, and we’re helping professionals learn more about our specialized practice with actionable information. The need for specialized tools in mental healthcare has never been greater,” said Dr. Thayer.
Zoe Boyer writes about her lifelong struggle with depression: “Over the years I tried every available treatment. I stayed in psychiatric hospitals, underwent years of therapy and tried a pharmacy’s worth of antidepressants, but my condition never improved. One day, I stumbled across an article on the use of ketamine as a promising treatment for severe, unresponsive depression.” After four sessions, everything changed. “When my brother got his first pair of glasses, he marveled that he could see individual leaves on trees. Ketamine felt a lot like that. To be in awe of simple pleasures felt like reason enough to live, and I was overcome with a quiet revelation: this is what it means to be content.” Zoe’s story is similar to many who have had life changing experiences with Ketamine. We see it every day at our Cedar Psychiatry clinics. This video shares the stories of just a few of the thousands of patients we’ve treated.
How one state senator’s bill to decriminalize psilocybin, MDMA, LSD, DMT, mescaline and ibogaine is gaining steam in California. Former army rangers and marine corps veterans are quoted about how psychedelics offered them something they found nowhere else: hope and lasting change. “I will say this unequivocally psychedelics have, and will, save veteran lives.”
Green Market Report covers our strategic investment of $1 million in a Stealth Mode Drug Development Company. Psychedellux recaps the top business stories in the psychedelic medicine industry.
Last week we announced a strategic investment of $1 million in a stealth mode drug development company based in the United States.
Report on Psychedelics covers our Frontline KAP program, which addresses a glaring need for innovative mental health solutions to provide treatment to healthcare workers suffering stress and trauma caused by Covid-19.
COVID-19 put a toll on the mental health of frontline healthcare workers. Novamind and the Wholeness Center will launch a ketamine-assisted psychotherapy protocol, in Utah and Colorado.
Dr. Thielking will oversee all aspects of the Company’s investigator-led studies, originating within Novamind’s best-in-class research sites, and leveraging its contract research organization (CRO) expertise to pursue additional clinical trial mandates from leading psychedelic drug developers.
“Advancing clinical research for psychedelic medicine to address treatment-resistant mental illnesses and supporting patients by developing novel approaches to care for underserved conditions like cancer-related depression, is the next step in my life’s work,” said Dr. Thielking.
It’s a lawsuit that may be more of an “educational vehicle” for the Justice Department and the DEA than a legal battle. Under Washington state’s Right to Try law, Erinn Baldeschwiler should have the right to use psilocybin therapeutically, but the DEA has denied her request. Baldeschwiler may only have two years left and doesn’t want those years to be marred by depression. This case could set a precedent for the future “if the case passes, the next doctor and patient who want access to psilocybin for end-of-life distress shouldn’t need to take it to court again.” We understand the positive impact psychedelic medicine can have and will watch this case closely as we prepare to bring more psychedelic-assisted psychotherapies to the world. This week, Novamind announced Dr. Paul Thielking as Chef Scientific Officer. Dr. Thielking will lead the development of Novamind’s psychedelic therapy protocols for conditions including cancer-related depression and end-of-life anxiety, available as treatments for clients and educational programs for clinicians.
Could changing the approach to the medical model transform the way we treat people? It’s a concept Natasha Fearnley believes in. “I’m beginning to guide them [people] through their journey. And I can’t imagine doing that without ever having any psychedelic experience.” TheraPsil agrees. “The non-profit believes that in order for healthcare professionals to deliver this “unique therapeutic modality” it’s essential that they undergo their own psilocybin journeys and guide their peers through the psilocybin therapy process.”
Posted by AGORACOM-JC
at 2:23 PM on Wednesday, June 23rd, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
” Demand for higher purity Silicon, materials that the PUREVAP QRR was designed to produce – but one that traditional silicon producers have a difficult time making, is about to enter a massive growth phase, driven by worldwide demand from the silicones, solar, and batteries industries. The Covid-19 pandemic accelerated the closing of old inefficient traditional Silicon plants and combining this with the chronic under investment in new conventional Silicon plants that occurred in the past decade, and the need for more efficient and environmentally friendly processes has created a perfect storm for the industry. HPQ should be a key beneficiary of this new reality.”
Posted by AGORACOM-JC
at 12:18 PM on Wednesday, June 23rd, 2021
Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
Strong psychedelic drug development pipeline targeting Addiction.
First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
Multiple scalable revenue streams across drug development and clinical delivery.
Toronto, Ontario–(June 23, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (“Awakn” or the “Company“) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”.
“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. “The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.”
The listing follows the successful completion of the previously announced reverse takeover of a Canadian public company, 2835517 Ontario Ltd., by Toronto-based Awakn Life Sciences Inc. The public company was subsequently renamed Awakn Life Sciences Corp. in connection with the reverse takeover and the listing on the NEO. Additionally, the Company raised gross proceeds of approximately USD$8.3 million through a brokered private placement.
Awakn engaged Canaccord Genuity Corp. and Eight Capital as co-lead agent and joint bookrunners to complete the brokered financing. In connection with the transaction, 2835517 Ontario Ltd. was de-listed from the NEX board of the TSX Venture Exchange.
A filing statement with information about Awakn prepared in accordance with the policies of the NEO is available on SEDAR at www.sedar.com.
About Awakn Life Sciences
Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.
Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.
Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Investor Enquiries: KCSA Strategic Communications Valter Pinto / Tim Regan Phone: +1 (212) 896-1254 [email protected]
Media Enquiries: America and Canada: KCSA Strategic Communications Anne Donohoe [email protected]
Rest of World: ROAD Communications Paul Jarman / Anna Ramsey [email protected]
Posted by AGORACOM-JC
at 12:14 PM on Wednesday, June 23rd, 2021
To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.
Awakn has a dual strategic focus:
Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally.
Notable Highlights include:
Strategic focus on better treating Addiction with psychedelics.
World leading team focused on psychedelic drug and therapy research.
Strong drug and therapy development pipeline, specifically targeting Addiction.
Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery
Closed $8.3M June 8
BRAND NEW LISTING … commencing trading on NEO
Sit back, relax and watch this powerful interview with CEO Anthony Tennyson.
Posted by AGORACOM-JC
at 9:06 AM on Saturday, June 19th, 2021
A weekly summary of Novamind news and media, including the announcement of a US$1,000,000 strategic investment in a Stealth Mode Drug Development Company.
“Novamind has over five years of operational expertise with psychedelic medicine, a track record of innovative treatment protocol development, and strong clinical research partnerships with blue-chip pharmaceutical companies,” said CEO Yaron Conforti. “I’m excited to share our vision for the next chapter of mental health treatment at the Conference.”
The Strategic Investment leverages Novamind’s expertise in patient recruitment and patient management for the Investee’s development of novel treatments for neuropsychiatric disorders.
Global News paints a compelling picture about the need for psychedelic-assisted therapy in Canada. “I just had so many different experiences, where all my questions that I had written out, everything was answered for me.” says Laurie Brooks, who was diagnosed with colon cancer at age 54. “I’m able now to deal with the emotions as they come, and to sit with them and hold them.”
It’s been a year of progress as many health breakthroughs happened while the public’s attention was rightfully focused on a Covid vaccine. Time covers some significant steps forward, including a malaria vaccine that could help save some 400,000 lives a year and the promising results of MDMA and psilocybin studies. It’s important to note the therapy aspect of the psychedelic studies. Both MDMA and psilocybin were given to participants in conjunction with therapy. Yes, these drugs are powerful and help provide the right mindset for improving mental health, but it’s the therapy that really creates lasting change. And it’s why that’s such a big part of what we do at Novamind.
Congratulations to Atai Life on listing to the Nasdaq. As an early strategic investor, we look forward to seeing Atai continue to deliver on its mission of “pioneering the development of highly effective mental health treatments.” Christian Angermayer
Green Market Report covers our fiscal Q3 earnings in their Psychedellux recap of the top business stories in the psychedelic medicine industry.
Novamind reported total revenue of $1.8 million, a 43% quarter-over-quarter, driven by increased patient volume at the Company’s four operating clinics.
“Together with the Wholeness Center, we’re joining forces to offer a new therapy that will positively impact the people who show up every day and continue to provide critical healthcare for the public during—and after—this difficult time,” said Dr. Robison.
From GQ’s series on mental health comes a piece about the psychological reasons how new experiences can change how we perceive time and make us more resilient. It’s an interesting read and the author even compares trees blooming in spring to psychedelics. “Even the most mundane new experiences left me feeling genuinely elated.” There’s a reason for it too. From Dr. Laurie Santos, “Novel stimuli tend to activate regions of our brain that are associated with rewards.” At our Cedar Psychiatry clinics, we practice a holistic approach to mental health. Taking into account psychological, biological, social, environmental, and cultural influences. Learn more here.
We’ve always believed in Atai’s vision to transform the treatment of mental health disorders. It’s why we became early strategic investment partners. Congratulations to Atai Life Sciences on launching their initial public offering.
